Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $30.17.

Separately, Needham & Company LLC lifted their target price on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CELC. Soleus Capital Management L.P. lifted its position in Celcuity by 106.0% during the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock worth $33,577,000 after purchasing an additional 1,319,700 shares during the period. Baker BROS. Advisors LP raised its position in shares of Celcuity by 42.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company’s stock valued at $35,062,000 after buying an additional 803,575 shares in the last quarter. State Street Corp lifted its holdings in shares of Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after acquiring an additional 668,318 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Celcuity during the 4th quarter worth approximately $8,468,000. Finally, Candriam S.C.A. bought a new position in Celcuity in the fourth quarter valued at approximately $3,450,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ:CELC opened at $10.24 on Friday. The stock has a 50 day simple moving average of $11.20 and a 200 day simple moving average of $12.96. The stock has a market cap of $380.21 million, a P/E ratio of -3.92 and a beta of 0.65. Celcuity has a 1-year low of $8.53 and a 1-year high of $22.04. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.